Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Aliment Pharmacol Ther. 49(4):408–18. February 2019.